0
Summaries for Patients |

The Cost-Effectiveness of Cardiac Resynchronization Therapy for Heart Failure FREE

[+] Article and Author Information

The summary below is from the full report titled “Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure.” It is in the 7 September 2004 issue of Annals of Internal Medicine (volume 141, pages 343-351). The authors are G. Nichol, P. Kaul, E. Huszti, and J.F.P. Bridges.


Ann Intern Med. 2004;141(5):I-29. doi:10.7326/0003-4819-141-5-200409070-00104
Text Size: A A A

What is the problem and what is known about it so far?

In heart failure, the heart does not pump blood as well as it should and fluid builds up in the lungs. The symptoms of heart failure include difficulty breathing, decreased ability to exercise, and leg swelling. Although many drugs help patients with heart failure, there is no cure. The condition is disabling and even fatal for many patients. In patients with heart failure, conduction of electrical impulses through the heart is often abnormal. This abnormal conduction, in turn, can lead to uncoordinated contraction of the ventricles, the large pumping chambers of the heart. Cardiac resynchronization is a newer heart failure treatment that uses a special type of pacemaker to synchronize the contraction of the ventricles. A review in this same issue of Annals of Internal Medicine shows that cardiac resynchronization improves quality of life, exercise ability, and survival for selected patients with heart failure. However, the economic impact of this new heart failure therapy is unclear.

Why did the researchers do this particular study?

To estimate the economic impact of cardiac resynchronization therapy for heart failure.

Who was studied?

Rather than studying actual patients, the researchers used computers to simulate what would happen to a “virtual” group of patients with heart failure.

How was the study done?

The researchers used published information to estimate what might happen (and how much it would cost) if doctors treated patients with symptomatic heart failure and prolonged QRS on electrocardiography with usual drug therapy or with cardiac resynchronization. They put these estimates into the computer model and calculated how much each strategy would cost per year of life that it saved. The computer model also accounted for the quality of life during the years that patients survived.

What did the researchers find?

Compared with drug therapy, cardiac resynchronization therapy cost about $90 000 more per quality-adjusted life-year it saved. These costs are in line with what U.S. society pays for other heath interventions. However, the estimates of cost-effectiveness were sensitive to changes in the assumptions for several key factors, including the estimates of the effect of resynchronization on hospitalization and death.

What were the limitations of the study?

The study was a computer simulation, so we cannot be sure what the results would be with actual patients.

What are the implications of the study?

The cost-effectiveness of cardiac resynchronization therapy is similar to that of other commonly used medical therapies.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)